Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Curcumin Versus Ibuprofen for Exercise-Induced Muscle Damage in Physically Active Women (CURACTIVE)

20 août 2026 mis à jour par: Diego Fernández Lázaro, University of Valladolid

Comparative Efficacy of Oral Curcumin Supplementation Versus Ibuprofen on Exercise-Induced Muscle Damage, Inflammation, Oxidative Stress, and Sports Performance in Physically Active Women: A Randomized Double-Blind Placebo-Controlled Trial

xercise-induced muscle damage (EIMD) is a common consequence of unaccustomed or high-intensity exercise and is characterized by muscle soreness, impaired physical performance, inflammation, oxidative stress, and increased circulating biomarkers of muscle damage. Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are frequently used to alleviate these symptoms, although their repeated use may be associated with adverse effects. Curcumin, a natural polyphenol with antioxidant and anti-inflammatory properties, has emerged as a potential nutritional strategy to support post-exercise recovery.

This randomized, double-blind, placebo-controlled trial aims to compare the effects of oral curcumin supplementation and ibuprofen administration on exercise-induced muscle damage in physically active women. The study evaluates clinical outcomes, physical performance, biomarkers of muscle damage, inflammation, oxidative stress, and other health-related biomarkers to determine whether curcumin may represent a safe and effective nutritional alternative for promoting recovery after eccentric exercise.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

Exercise-induced muscle damage (EIMD) following eccentric exercise is characterized by structural disruption of skeletal muscle fibers accompanied by transient inflammation, oxidative stress, delayed-onset muscle soreness, and impaired physical performance. Although these responses are considered part of the normal adaptive process, excessive muscle damage may delay recovery and impair subsequent training or competition.

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used by athletes to reduce post-exercise pain and inflammation. However, repeated NSAID use has been associated with gastrointestinal, renal, and cardiovascular adverse effects, highlighting the need for safe nutritional alternatives capable of supporting recovery without interfering with physiological adaptation.

Curcumin, the principal bioactive polyphenol derived from Curcuma longa, exhibits antioxidant, anti-inflammatory, and cytoprotective properties through modulation of multiple molecular pathways involved in redox homeostasis and inflammatory signaling. Experimental and clinical studies suggest that curcumin may attenuate exercise-induced muscle damage by reducing oxidative stress, inflammatory responses, and muscle soreness, although evidence remains inconsistent and direct comparisons with NSAIDs are scarce.

The objective of this randomized, double-blind, placebo-controlled trial is to compare the efficacy of oral curcumin supplementation with ibuprofen and placebo in physically active women following eccentric exercise. The study evaluates clinical recovery, physical performance, biomarkers of muscle damage, inflammatory and oxidative stress biomarkers, and additional health-related biomarkers in order to characterize the physiological effects of curcumin supplementation and determine its potential role as a nutritional strategy for exercise recovery.

Type d'étude

Interventionnel

Inscription (Réel)

36

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Espagne
      • Soria, Espagne, 42004
        • University Campus of Soria

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

Healthy physically active women. Age within the predefined study range. Regular participation in physical activity for at least 6 months before enrollment.

Ability to perform the eccentric exercise protocol. Written informed consent provided before participation.

Exclusion Criteria:

Current musculoskeletal injury or pain affecting exercise performance. History of cardiovascular, metabolic, neurological, renal, hepatic, or inflammatory disease.

Pregnancy or breastfeeding. Current use of anti-inflammatory drugs, antioxidant supplements, or other nutritional supplements that could interfere with study outcomes.

Known allergy or intolerance to curcumin, turmeric, ibuprofen, or study ingredients.

Smoking or excessive alcohol consumption. Participation in another clinical trial during the study period. Any condition considered by the investigators to compromise participant safety or protocol compliance.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Curcumin
Participants received oral curcumin supplementation according to the study protocol before and following the eccentric exercise protocol. Clinical recovery, physical performance, muscle damage, inflammatory, oxidative stress, antioxidant defense, and other health-related biomarkers were evaluated during the recovery period.
Complément alimentaire: Curcumin
Participants received oral curcumin supplementation according to the study protocol before and after the eccentric exercise protocol. Curcumin was administered at the predefined dose and duration specified in the protocol. The intervention aimed to evaluate its effects on exercise-induced muscle damage, inflammation, oxidative stress, antioxidant defense, physical performance, and recovery in physically active women.
Autres noms:
  • Curcuma longa
Comparateur actif: Ibuprofen
articipants received oral ibuprofen according to the study protocol before and following the eccentric exercise protocol. Clinical recovery, physical performance, muscle damage, inflammatory, oxidative stress, antioxidant defense, and other health-related biomarkers were evaluated during the recovery period.
Médicament: Ibuprofen
Participants received oral ibuprofen according to the study protocol before and after the eccentric exercise protocol. Ibuprofen was administered at the predefined dose and duration specified in the protocol and served as the active comparator for evaluating recovery following exercise-induced muscle damage.
Comparateur placebo: Placebo
Participants received placebo capsules identical in appearance to the active interventions according to the study protocol before and following the eccentric exercise protocol. Clinical recovery, physical performance, muscle damage, inflammatory, oxidative stress, antioxidant defense, and other health-related biomarkers were evaluated during the recovery period.
Autre: Placebo
Participants received placebo capsules identical in appearance, packaging, and administration schedule to the active interventions. The placebo contained inert ingredients and was administered according to the study protocol before and after the eccentric exercise protocol.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Exercise-induced muscle damage
Délai: Baseline and during the 72-hour recovery period following eccentric exercise.
Exercise-induced muscle damage assessed using clinical outcomes and biochemical biomarkers following eccentric exercise to compare the effects of oral curcumin supplementation, ibuprofen, and placebo in physically active women.
Baseline and during the 72-hour recovery period following eccentric exercise.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Creatine kinase (CK)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum creatine kinase concentration as a biomarker of exercise-induced skeletal muscle damage following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Lactate dehydrogenase (LDH)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum lactate dehydrogenase concentration as an indicator of muscle membrane disruption and tissue damage.
Baseline and during the 48-hour recovery period following eccentric exercise.
Aspartate aminotransferase (AST)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum aspartate aminotransferase concentration as an indirect biomarker of exercise-induced muscle tissue damage.
Baseline and during the 48-hour recovery period following eccentric exercise.
Alanine aminotransferase (ALT)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum alanine aminotransferase concentration following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Alkaline phosphatase (ALP)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum alkaline phosphatase concentration following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Interleukin-6 (IL-6)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in circulating interleukin-6 concentration as a biomarker of the inflammatory response to exercise-induced muscle damage.
Baseline and during the 48-hour recovery period following eccentric exercise.
C-reactive protein (CRP)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum C-reactive protein concentration as a marker of systemic inflammation following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Malondialdehyde (MDA)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in plasma malondialdehyde concentration as a biomarker of lipid peroxidation and oxidative stress.
Baseline and during the 48-hour recovery period following eccentric exercise.
Superoxide dismutase (SOD)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in superoxide dismutase activity as an indicator of endogenous antioxidant defense.
Baseline and during the 48-hour recovery period following eccentric exercise.
Catalase (CAT)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in catalase activity as a marker of antioxidant defense following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Delayed-onset muscle soreness (DOMS)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in perceived muscle soreness assessed using a validated visual analogue scale following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Countermovement jump (CMJ)
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in countermovement jump performance as a measure of lower-limb neuromuscular function and exercise recovery.
Baseline and during the 48-hour recovery period following eccentric exercise.
Thigh circumference
Délai: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in thigh circumference as an indirect indicator of exercise-induced muscle swelling.
Baseline and during the 48-hour recovery period following eccentric exercise.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

University of Valladolid

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

31 janvier 2026

Achèvement primaire (Réel)

23 mai 2026

Achèvement de l'étude (Réel)

1 août 2026

Dates d'inscription aux études

Première soumission

20 août 2026

Première soumission répondant aux critères de contrôle qualité

20 août 2026

Première publication (Réel)

25 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • DFL-CURC-2025-01

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

ndividual participant data that underlie the results reported in publications arising from this study (after de-identification) will be made available upon reasonable request to the corresponding investigator. Data will be shared with researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the study investigators and complies with applicable ethical and institutional regulations.

Délai de partage IPD

Beginning 6 months after publication and ending 5 years after publication.

Critères d'accès au partage IPD

Data will be available upon reasonable request to qualified researchers for scientifically sound research purposes following approval by the study investigators and execution of a data sharing agreement, when required.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner